As antiretroviral therapy has improved life expectancy in human immunodeficiency virus (HIV) infection, the life-limiting complication of HIV‐related pulmonary hypertension has come into focus. Inhalation of the stable prostacyclin analogue iloprost is an effective treatment for various forms of precapillary pulmonary hypertension. The main objective of the present study was to evaluate the safety and efficacy of inhaled iloprost in HIV‐related pulmonary hypertension.
In eight patients with severe pulmonary hypertension related to HIV infection, right heart and femoral artery catheterisation were performed. The acute effect of oxygen, inhaled nitric oxide and aerosolised iloprost was investigated. Four patients underwent long-term treatment with inhaled iloprost.
The rank order of pulmonary vasodilatory potency was iloprost>NO>O2, with a maximum reduction (mean±sem) in pulmonary vascular resistance of 30.6±3.1% (p<0.001), 5.9±3.9% and −0.6±3.9%, respectively. Concomitantly, inhaled iloprost significantly increased the cardiac index and central venous oxygen saturation. Chronic treatment with inhaled iloprost tended to improve the 6 min walking distance and decreased pulmonary vascular resistance in all patients (although not significantly). No serious adverse events and no major interactions with the ongoing antiretroviral therapy were noted.
In conclusion, inhaled iloprost is a potent pulmonary vasodilator in human immune deficiency virus-related pulmonary hypertension. Future studies are warranted to confirm the encouraging long-term beneficial results observed in the present limited number of patients.
- acquired immune deficiency syndrome
- human immunodeficiency virus
- pulmonary hypertension
This study was supported by the German Research Foundation (Collaborative Research Centre 547).
Severe pulmonary hypertension is a debilitating disease resulting in short life expectancy and often affecting young people 1. The association between human immune deficiency virus (HIV) infection and increased risk of development of chronic pulmonary hypertension is well documented 2–4. The mechanisms underlying this coincidence are, however, not yet established. Owing to the similarities between the pathology and clinical course of HIV‐associated pulmonary hypertension and primary pulmonary hypertension (PPH), both entities (among others) belong to the same class of pulmonary arterial hypertension (PAH) according to the new World Health Organization (WHO) classification 5. Treatment of HIV patients with antiretroviral therapy (ART) has dramatically improved the quality of life and life expectancy of these patients since the late 1990s 4, 6–8. Owing to the better prognosis of ART‐treated patients, severe pulmonary hypertension more commonly represents the life-limiting complication in these patients 9.
There is little to offer patients at the moment with regard to therapy of pulmonary hypertension in HIV. Analogous to PPH, continuous intravenous administration of epoprostenol has been proposed for treatment of HIV‐associated PAH 10. This therapy is known to improve exercise capacity and survival in patients with PPH 11. However, this approach can be hampered by serious infectious complications of the intravenous line, systemic side-effects due to the nonselectivity of the vasodilatory effect and the comparably high costs of the therapy. Inhalation of aerosolised iloprost, a long-acting prostacyclin analogue, was recently shown to cause strong preferential pulmonary vasodilatation in both primary and secondary pulmonary hypertension 12, 13. Long-term use of nebulised iloprost was found to be beneficial in severe PPH, even when associated with overt right heart failure 14–16. The aim of the present study was to evaluate the safety and efficacy of inhaled iloprost in HIV‐related PAH. Additionally, long-term iloprost therapy was investigated in four patients with stable HIV infection undergoing ART.
Eight patients (five females and three males) with severe pulmonary hypertension (mean pulmonary arterial pressure >35 mmHg) were included in the study. All patients suffered from HIV infection and concomitantly from pulmonary arterial hypertension, as defined by the WHO world symposium on pulmonary hypertension held in Evian, France 5. All patients were admitted to the University Hospital (Justus Liebig University Giessen, Giessen, Germany) for diagnosis and therapy of the underlying HIV infection and testing of pulmonary vasoreactivity with evaluation of therapeutic options. The major exclusion criteria were: pulmonary hypertension secondary to chronic obstructive pulmonary disease, pulmonary venous congestion, congenital heart disease, acute or chronic inflammatory lung disease, pregnancy or insufficient contraceptive measures, and previous treatment with prostanoids. The individual response rate to vasodilators, including inhaled nitric oxide, did not represent an inclusion or exclusion criterion.
The study protocol, requiring right heart and femoral artery catheterisation, was approved by the Justus Liebig University Giessen Ethics Committee, and each patient gave written informed consent. Vasodilator testing was carried out as follows, and, if necessary, patients received nasal oxygen throughout the entire test procedure in order to achieve an arterial oxygen saturation of >88%. Each patient underwent short-term NO inhalation, with the maximum vasodilatory response to this agent requiring 20–40 parts per million NO. After haemodynamic parameters had returned to baseline levels, iloprost inhalation was performed using an ultrasonic nebuliser (Multisonic compactTM; Otto Schill, Probstzella, Germany; mass median aerodynamic diameter 3.9 µm; 4 min inhalation period; total inhaled dose 2.8 µg iloprost) 17. Haemodynamic and gas exchange parameters were measured 5, 15, 30, 60, 90 and 120 min after iloprost inhalation.
All data are presented as mean±sem. For each parameter, the response to vasodilator treatment was considered significant if the 95% (p<0.05), 99% (p<0.01) or 99.9% (p<0.001) confidence interval compared to pretreatment values did not overlap with zero. The Kruskal-Wallis test was used to determine a difference in haemodynamic responsiveness to the applied vasodilators.
Patient characteristics and concomitant medication
Baseline haemodynamic parameter values are given in table 1⇓, consistently showing severe pulmonary arterial hypertension and low cardiac indices. Left ventricular impairment was excluded by means of echocardiography and this is additionally documented by the low wedge pressures in each patient. Patient characteristics, including ongoing medication, are listed in table 2⇓.
Vasodilator testing during right heart catheterisation
Oxygen supply resulted in a significant increase in arterial oxygen tension (Pa,O2; 9.12±2.50 kPa (46.0±18.8 mmHg), p<0.05) and mixed venous oxygen saturation (8.4±2.9%, p<0.01) (fig. 1⇓). Despite some reduction in pulmonary arterial pressure, pulmonary vascular resistance (PVR) did not change. This was mainly attributed to a significant reduction in cardiac output (4.1±1.6%, p<0.01) (fig. 1⇓).
Nitric oxide inhalation
NO inhalation did not influence pulmonary or systemic haemodynamics significantly. No alteration in gas exchange was noted (fig. 1⇑).
Inhalation of iloprost reduced PVR by 30.6±3.1% (p<0.001) and increased the cardiac index by 20.9±8.9% (p<0.01) (fig. 1⇑). The decrease in the PVR/systemic vascular resistance (SVR) ratio indicated preferential pulmonary vasodilatation. Central venous oxygen saturation increased significantly, whereas the Pa,O2 remained unchanged. The iloprost effects levelled off within 120 min after nebulisation, as demonstrated for PVR in figure 2⇓.
Chronic therapy with iloprost inhalation
Of the eight patients, four agreed to undergo chronic therapy with inhaled iloprost (6–9 inhalations·day−1). All patients were treated with oral anticoagulants for ≥3 months before inclusion in the study and this medication was continued during long-term treatment with iloprost. None of the patients were treated with digoxin. The dosage of diuretics (in all cases, a combination of spironolactone with furosemide) was unchanged during the observation period. In all of these patients, no significant changes in parameters of HIV infection were detectable during the course of chronic iloprost therapy (CD4 cell densities in patients 1–4 were 748 (702 after 6 months), 710 (680), 266 (320) and 820 (835) cells·µL−1; HIV ribonucleic acid (RNA) levels remained below the detection limit in three of the four cases, and were changed from 300 copies·mL−1 before treatment in patient No. 3 to below the detection limit after the 6‐month observation period). Two patients classified in New York Heart Association Functional Class IV at baseline improved to Class III, and two patients previously in Class III improved to Class II, after 6 months of chronic iloprost therapy. All patients were satisfied with iloprost therapy. On average, the 6 min walking distance at baseline was 331±21 m. Over a treatment period of 6 months, the walking distance increased to 417±40 m (p=0.063, Wilcoxon signed-rank test) in these patients (fig. 3⇓). Baseline PVR was 1,402±324 dyn·s·cm−5 (1 dyn·cm−2=0.1 Pa). After 6 months of continued inhalational iloprost therapy, it decreased to 772±89 dyn·s·cm−5 (p=0.065) (fig. 3⇓).
In the present study, inhalation of iloprost, a stable analogue of prostacyclin, markedly reduced PVR and increased cardiac output in patients with severe pulmonary hypertension related to HIV infection. Long-term administration of aerosolised iloprost improved exercise capacity and pulmonary haemodynamics.
All patients except one had been receiving long-term ART for ≥2 yrs before being tested in the present study. Stable T‐helper (CD4) cell counts and HIV RNA levels indicated stability of the underlying disease. All were closely monitored in the University Hospital HIV outpatient clinic. Changes in ART were only made for HIV‐related reasons. Severe pulmonary hypertension was noted in all patients. This was reflected by strongly elevated baseline pulmonary arterial pressures as well as low cardiac indices and low central venous oxygen saturation (table 1⇑). Diagnostic procedures, including elaborate imaging techniques, excluded other causes of pulmonary hypertension from HIV infection (e.g. thromboembolic disease, cardiac shunting, connective tissue disease, hepatic cirrhosis, etc.). Currently, little is known about the pathogenesis and natural course of HIV‐associated pulmonary hypertension. However, life expectancy is dramatically reduced (irrespective of CD4 cell counts) compared to the mean survival of HIV‐infected patients treated with ART as soon as manifest pulmonary hypertension is detectable 4, 9, 18, 19.
Application of nasal oxygen significantly increased arterial oxygenation and mixed venous oxygen saturation without inducing major changes in arterial or systemic haemodynamics. This indicates that hypoxic vasoconstriction, due to reduced Pa,O2, is not a major contributor to the pulmonary hypertension in these patients. The moderate decrease in pulmonary arterial pressure was paralleled by a minor, though significant, decrease in cardiac output and frequency, with PVR unchanged. Most probably, this reflects some reduction in the sympathetic drive due to adequate arterial oxygenation.
Inhaled NO is a selective pulmonary vasodilator in different types of acute and chronic pulmonary hypertension 20, 21. Pharmacological challenge with this agent during right heart catheterisation is widely accepted as a screening tool that helps identify patients who will respond favourably to long-term treatment with high doses of oral calcium channel blockers 22. A PVR reduction of ≥30% during NO inhalation is generally regarded as reflecting substantial vasoresponsiveness 21. In the present study, no patient was found to be a “NO‐responder”. In contrast to NO, inhaled iloprost caused a significant decrease in PVR, accompanied by a decrease in pulmonary arterial pressure and a substantial increase in cardiac output and central venous oxygen saturation. Together, this reflects improved oxygen delivery in these patients. Moreover, the decrease in the PVR/SVR ratio indicates preferential pulmonary as compared to systemic vasodilation, in response to the inhaled prostanoid. This observation, showing that inhaled iloprost is a more potent pulmonary vasodilator than NO in different types of pulmonary hypertension, is in accordance with previous findings from both the present authors' group and other investigators 12, 23.
Intravenous epoprostenol is an effective and life-saving therapy in PPH 11. Recent reports have been suggestive of a potential role for this therapy in HIV‐related pulmonary hypertension 9, 10, 14. The data of Nunes et al. 9 demonstrate that the use of a combination of ART and epoprostenol infusion is related to better survival in patients with severe HIV‐associated pulmonary hypertension, and, therefore, might be considered one therapeutic option in this patient group. However, the use of intravenous epoprostenol can be associated with at least three limiting drawbacks. First, the lack of pulmonary selectivity of the vasodilatory effect results in systemic side-effects. Secondly, development of tolerance may make progressive dosage increase necessary. Thirdly, serious infections may occur via the intravenous delivery line 24. Application of prostanoids via inhalation is an appealing concept for circumventing most of these shortcomings of infusion therapy 12. Indeed, chronic inhalation of iloprost was shown to be an effective and well-tolerated therapy for PPH and some forms of nonprimary pulmonary hypertension in a recent multicentric trial 25. In the present investigation, four patients received long-term inhaled iloprost therapy on a compassionate treatment basis. As shown in previous studies, this type of prostanoid therapy was well tolerated, no serious adverse events were reported and all patients were satisfied with iloprost therapy. Moreover, exercise capacity (6 min walking distance) increased and PVR decreased in all patients over a 6‐month observation period. Although uncontrolled, these consistent changes strongly suggest efficacy of iloprost in HIV‐associated pulmonary hypertension. In addition to this nonparenteral therapeutic approach, new oral treatments are currently under investigation for several forms of chronic pulmonary hypertension. The endothelin receptor antagonist bosentan is already of proven efficacy in the treatment of PAH 26. However, to date, no data have been published about its use in patients with HIV and pulmonary hypertension. In the European phase III trial with oral beraprost, in addition to the majority of patients who had PAH (including those with PPH and pulmonary hypertension associated with collagen vascular disease), a few patients with HIV‐associated pulmonary hypertension were included 27. In this study in particular, the subgroup of patients with PPH showed beneficial clinical effects. Recently, the successful use of the oral phosphodiesterase 5 inhibitor sildenafil has been reported in a small series of patients with HIV‐associated pulmonary hypertension 28.
In conclusion, inhaled iloprost showed pulmonary vasodilatory potency in patients with human immunodeficiency virus infection-related pulmonary hypertension. Patients treated long-term with the aerosolised prostanoid might show improvements in exercise capacity and pulmonary haemodynamics. These encouraging observations, obtained in a limited number of patients, warrant further controlled studies on iloprost inhalation for the treatment of human immunodeficiency virus-associated pulmonary hypertension.
The authors are grateful to J. Yeager for thorough linguistic editing of the manuscript.
- Received May 26, 2003.
- Accepted September 5, 2003.
- © ERS Journals Ltd